Dexcom Beats on Q3, Raises 2026 Guidance and Authorizes $1.0 Billion Buyback
DXCM sits 46% above its 52-week low of $54.11.
Summary
Dexcom grew Q3 revenue 11% to $1.344 billion, raised full-year revenue and margin guidance, and authorized a $1.0 billion share buyback through 2027.
Key Events · Earnings and Guidance · DXCM
-
Q3 Revenue Up 11% to $1.344 Billion
Worldwide revenue rose to $1.344 billion from $1.209 billion a year earlier, with U.S. revenue up 14% and international up 5%.
-
Operating Margin Expands 420 Basis Points
GAAP operating income reached $327.2 million, or 24.3% of revenue, versus $242.5 million and 20.1% in Q3 2025; non-GAAP operating income was $339.5 million, or 25.3% of revenue.
-
Full-Year Guidance Raised
Revenue guidance midpoint lifted to $5.20-$5.25 billion (approximately 12-13% growth), with non-GAAP operating margin now approximately 24% and Adjusted EBITDA margin approximately 32%.
-
$1.0 Billion Buyback Authorized
The board approved repurchases of up to $1.0 billion of common stock through December 31, 2027, funded against $1.82 billion of cash and marketable securities with the revolving credit facility undrawn.
Analysis · DXCM · Industrial Applications And Services
Dexcom delivered Q3 revenue of $1.344 billion, up 11% year over year, and pushed GAAP operating income to $327.2 million — 24.3% of revenue, a 420 basis point improvement. More important for the thesis, management raised the midpoint of full-year revenue guidance to $5.20-$5.25 billion and lifted the non-GAAP operating margin target to roughly 24% and Adjusted EBITDA margin to about 32%, extending a margin-expansion story that began earlier this year. Layered on top is a new $1.0 billion share repurchase authorization running through December 31, 2027, backed by $1.82 billion of cash and marketable securities with the revolver undrawn. The buyback does not offset the dilution risk of any future financing, but it does put a real bid under the stock and shows the board sees the shares as undervalued relative to cash generation.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DXCM was trading at $79.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $54.11 to $92.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.